Zoetis (ZTS) may be one of the most interesting “quality in the doghouse” setups of 2026. The global animal-health leader is still profitable, institutionally loved, and backed by powerful pet-humanization trends — yet soft U.S. pet spending, competition, and lowered guidance have crushed the stock. With directors buying near the lows and forward P/E near 11x, is ZTS finally becoming a value play?

Read entire article

Intel finally looks like a company moving in the right direction. AI demand is accelerating, the balance sheet is stronger, Intel Foundry could reshape the company's future, and CEO Lip-Bu Tan is buying shares alongside investors. The turnaround appears increasingly credible. The valuation? That's where patience may still pay.

Read entire article

Garbage rarely excites investors. Bill Gates keeps buying it anyway. Republic Services combines recurring revenue, remarkable pricing power, an irreplaceable landfill network, and disciplined capital allocation—making it one of the market's most dependable compounders, even if its premium valuation warrants patience.

Read entire article

Artificial intelligence doesn't just require better chips—it requires vastly more electricity. Ameresco sits at the intersection of AI infrastructure, energy modernization, and microgrids, backed by a record $6.73 billion backlog, significant insider buying, and improving operational momentum. The opportunity is compelling, but so are the risks.

Read entire article

After falling roughly 46% from its all-time high, Tractor Supply has become one of retail's more intriguing turnaround candidates. CEO Hal Lawton recently invested more than $500,000 of his own money while institutions continue to own over 95% of the company. We examine whether today's valuation reset represents genuine opportunity—or simply reflects slowing fundamentals that still need to improve.

Read entire article

SiteOne Landscape Supply isn't flashy—but it may be one of the market's most overlooked industrial compounders. After a sharp correction, CEO Doug Black invested more than $816,000 of his own money while institutions continue to dominate the shareholder base. We examine the valuation, competitive moat, earnings, risks, and whether this roll-up story deserves another look.

Read entire article

Boston Scientific's stock has been cut nearly in half from its peak, yet the business remains fundamentally strong. With CEO Mike Mahoney buying $9 million worth of shares, a remarkably low 0.71 PEG ratio, billions in annual free cash flow, and overwhelming institutional ownership, is Wall Street overlooking one of healthcare's most attractive GARP opportunities?

Read entire article

Bunge isn't merely a grain trader—it's one of the world's most important agricultural infrastructure companies. After a 43% rally from our 2025 recommendation, a healthy pullback, another insider purchase, stronger earnings guidance and accelerating Viterra synergies make the long-term investment story compelling once again.

Read entire article

Huntsman isn't simply a cyclical chemical company anymore. Between repeated insider buying, a transformational $12.5 billion merger with Olin, trading at just 0.64x book value and more than $400 million in projected synergies, investors may be looking at one of the market's more intriguing industrial turnaround opportunities.

Read entire article

Ionis Pharmaceuticals (NASDAQ: IONS) lost billions in market value after a disappointing clinical trial—but one director immediately bought more than $1 million worth of shares. Is Wall Street missing the bigger RNA platform story? Here's the full analysis.

Read entire article